Patents by Inventor Joachim Kempeni

Joachim Kempeni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
    Publication number: 20130004507
    Abstract: Methods of treating disorders in which TFN? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: June 22, 2012
    Publication date: January 3, 2013
    Applicant: Abbott Biotechnology Ltd.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES
    Publication number: 20120177596
    Abstract: Methods of treating disorders in which TFN? activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor ? (hTNF?) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF? (e.g., Kd=10?8 M or less), a slow off rate for hTNF? dissociation (e.g., Koff=10?3 sec?1 or less) and neutralize hTNF? activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: November 3, 2011
    Publication date: July 12, 2012
    Applicant: ABBOTT BIOTECHNOLOGY LTD.
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Methods of administering anti-TNFalpha antibodies
    Publication number: 20030235585
    Abstract: Methods of treating disorders in which TFN&agr; activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor &agr; (hTNF&agr;) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNF&agr; (e.g., Kd=10−8 M or less), a slow off rate for hTNF&agr; dissociation (e.g., Koff=10−3 sec−1 or less) and neutralize hTNF&agr; activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Kits containing a pharmaceutical composition and instructions for dosing, and preloaded syringes containing pharmaceutical compositions are also encompassed by the invention.
    Type: Application
    Filed: June 5, 2002
    Publication date: December 25, 2003
    Inventors: Steven A. Fischkoff, Joachim Kempeni, Roberta Weiss
  • Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
    Publication number: 20010010819
    Abstract: The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.
    Type: Application
    Filed: February 14, 2001
    Publication date: August 2, 2001
    Applicant: Knoll Aktiengesellschaft
    Inventors: Roswitha Stenzel, Martin Kaul, Lothar Daum, Joachim Kempeni, Christa Raab, Sibylle Schaefer
  • Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6
    Patent number: 6235281
    Abstract: The invention relates to the use of TNF antagonists for producing drugs for the treatment of disorders characterized by elevated serum levels of interleukin-6.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: May 22, 2001
    Assignee: Knoll Aktiengesellschaft
    Inventors: Roswitha Stenzel, Martin Kaul, Lothar Daum, Joachim Kempeni, Christa Raab, Sibylle Schaefer
  • Products containing a lithium salt and a tumor necrosis factor
    Patent number: 5332571
    Abstract: The enhancement of the antitumor action of tumor necrosis factor by lithium salts is described.
    Type: Grant
    Filed: November 2, 1990
    Date of Patent: July 26, 1994
    Assignee: BASF Aktiengesellschaft
    Inventors: Joachim Kempeni, Michael Kluge, Walter Fiers